BioHarvest Launches VINIA SuperFood Functional Tea Line
BioHarvest Launches VINIA SuperFood Functional Tea Line
Incremental Product Launch Addresses $3.3 Billion North American Functional Tea Market Opportunity with First SuperFood Tea Infused with Piceid Resveratrol
增量產品推出首款注入 Piceid 白藜蘆醇的 SuperFood 茶,爲北美功能茶市場帶來了 33 億美元的機遇
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 25, 2024) - BioHarvest Sciences Inc. (NASDAQ: BHST) (CSE: BHSC) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced the launch of its highly anticipated VINIA infused teas - a line of SuperFood functional teas that deliver the same clinically validated benefits as the successful VINIA supplements. This launch further demonstrates the potential of VINIA's lifetime value across multiple consumer verticals.
不列顛哥倫比亞省溫哥華和以色列雷霍沃特--(Newsfile Corp.,2024年11月25日)——BioHarvest Sciences Inc.(納斯達克股票代碼:BHST)(CSE:BHSC)(FSE:8MV0)(「BioHarvest」 或 「公司」)是開創其專利植物合成技術平台的公司,今天宣佈推出備受期待的VINIA注入式茶——一系列超級食品功能茶提供與成功的 VINIA 補充劑相同的臨床驗證益處。此次發佈進一步展示了VINIA終身價值在多個垂直消費領域的潛力。
Tens of thousands of subscribers take VINIA daily to improve blood flow as a supplement in capsule form or through VINIA Superfood coffee, which increases their dilation of arteries, improving blood flow and enhancing their physical energy and mental alertness. Now consumers can experience those same blood flow improvements together with a cup of great tasting VINIA Superfood Tea, featuring four premium blends: Black Tea, Green Tea, Matcha Green Tea and Cranberry Hibiscus Herbal Tea.
成千上萬的訂閱者每天服用VINIA來改善血液流動,作爲膠囊形式的補充劑或通過VINIA Superfood咖啡服用,這會增加他們的動脈擴張,改善血液流動,增強他們的體能和精神警覺性。現在,消費者可以體驗同樣的血液流動改善以及一杯美味的 VINIA 超級食品茶,其中包含四種優質混合物:紅茶、綠茶、抹茶綠茶和蔓越莓芙蓉涼茶。
BioHarvest's VINIA SuperFood Infused Teas - which contain the equivalent piceid resveratrol contained in one capsule of VINIA - deliver superior science, efficacy and taste. Third party blind taste testing shows BioHarvest's VINIA infused teas outperformed leading English Breakfast and Green Tea brands. All the tea used in the VINIA SuperFood Infused Teas lineup are sourced from Rainforest Alliance certified farms.
BioHarvest 的VINIA SuperFood Infused Teas(一粒VINIA膠囊中所含的同等辛香白藜蘆醇)具有卓越的科學性、功效和口感。第三方盲味測試顯示,BioHarvest的VINIA浸泡茶的表現優於領先的英式早餐和綠茶品牌。VINIA SuperFood Infused Teas 系列中使用的所有茶都來自雨林聯盟認證的農場。
Ilan Sobel, Chief Executive Officer of BioHarvest, said: "Following the successful launch of our VINIA Capsules and VINIA SuperFood Coffee, we are now extending VINIA's circulatory health benefits to the tea category, executing our 'VINIA Inside' strategy to meet consumer demand across multiple VINIA delivery mechanisms.
BioHarvest首席執行官伊蘭·索貝爾表示:“繼成功推出VINIA膠囊和VINIA SuperFood Coffee之後,我們現在正在將VINIA的循環健康益處擴展到茶葉類別,執行我們的'VINIA Inside'戰略,通過多種VINIA交付機制滿足消費者的需求。
"We believe this new VINIA Superfood Functional Tea line will be a disruptor in the $3.3B functional tea market in North America[1], bringing unique benefits to the category with a product that is simply superior from a taste, science and efficacy perspective. From a financial perspective, the 'VINIA Inside' strategy has been designed to capture more gross profit dollars per unit while addressing a highly incremental, younger consumer base."
「我們相信,新的VINIA Superfood功能茶系列將顛覆北美33億美元的功能茶市場 [1],其產品從口味、科學和功效角度來看都非常出色,爲該類別帶來獨特的優勢。從財務角度來看,'VINIA Inside'戰略旨在獲得更多的單位毛利潤,同時滿足高度增量、年輕的消費者群體。」
BioHarvest will launch its VINIA infused tea line across major channels starting Saturday, December 7th, following a VIP launch commencing today for select existing VINIA subscribers.
BioHarvest將從12月7日星期六開始在主要渠道推出VINIA茶飲系列,此前將於今天開始爲部分現有VINIA訂閱者推出VINIA茶飲系列。
1Market Research Future - Global Functional Tea Market Overview - 2023
1市場研究未來-全球功能茶市場概述-2023
About BioHarvest Sciences Inc.
BioHarvest 科學公司簡介
BioHarvest Sciences Inc. (NASDAQ: BHST) (CSE: BHSC) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow the active ingredients in plants, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit .
BioHarvest Sciences Inc.(納斯達克股票代碼:BHST)(CSE:BHSC)(FSE:8MV)是植物合成領域的領導者,利用其專利技術平台在植物中種植活性成分,無需種植底層植物。BioHarvest正在利用其植物合成技術在兩個主要垂直業務領域開發基於科學且經過臨床驗證的下一代治療解決方案;作爲代表尋求複雜分子的客戶的合同開發和生產組織(CDMO),以及作爲專有營養保健品健康和保健產品(包括膳食補充劑)的創造者。要了解更多信息,請訪問。
Forward-Looking Statements
前瞻性陳述
Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Launching new products is subject to risks and uncertainties including the risk that the market will not accept the product or that government approvals required for sale or import of the products will not be obtained. There is never an assurance that any product set will successfully disrupt established product categories. There is no assurance that the Company will maintain or improve current financial performance, as revenues and margins are dependent on a combination of factors such as supply chain efficiencies, input cost stability, marketing efficiencies and uncertain consumer preferences. There is no guarantee that higher prices charged for new products will equate to higher profit margins or higher gross dollar profit per unit. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.
本新聞稿中提供的信息可能包括基於管理層當前估計、信念、意圖和預期的前瞻性陳述,並且存在許多風險和不確定性,這些風險和不確定性可能導致實際業績與前瞻性陳述中描述的結果存在重大差異。推出新產品面臨風險和不確定性,包括市場不接受該產品或無法獲得銷售或進口產品所需的政府批准的風險。永遠無法保證任何產品組合都會成功顛覆既定的產品類別。無法保證公司會維持或改善當前的財務業績,因爲收入和利潤率取決於供應鏈效率、投入成本穩定性、營銷效率和不確定的消費者偏好等多種因素。無法保證對新產品收取的更高價格將等於更高的利潤率或更高的每單位美元毛利潤。所有前瞻性陳述本質上都是不確定的,實際結果可能會受到我們無法控制的許多重大因素的影響。讀者不應過分依賴前瞻性陳述。除了通過我們的定期管理層討論和分析披露外,BHSC無意更新前瞻性陳述披露。
Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.
加拿大證券交易所及其監管服務提供商均不對本新聞稿的充分性或準確性承擔責任。
This release has been reviewed and approved by Dave Ryan, VP Investor Relations, who accepts responsibility for its contents.
本新聞稿已由投資者關係副總裁戴夫·瑞安審查和批准,他對其內容承擔責任。
BioHarvest Corporate Contact:
Dave Ryan, VP Investor Relations
+1 (604) 622-1186
info@bioharvest.com
BioHarvest 公司聯繫方式
投資者關係副總裁戴夫·瑞安
+1 (604) 622-1186
info@bioharvest.com
Investor Relations Contact:
Lucas A. Zimmerman
Managing Director
MZ Group - MZ North America
+1 (949) 259-4987
BHSC@mzgroup.us
投資者關係聯繫人:
盧卡斯·A·齊默爾曼
董事總經理
MZ 集團-MZ 北美
+1 (949) 259-4987
BHSC@mzgroup.us